Endocrine therapy in the years following a diagnosis of breast cancer: A proof of concept study using the primary care prescription database linked to cancer registration data

Gabrielle Emanuel*, Katherine E. Henson, John Broggio, Jackie Charman, Kieran Horgan, D. Dodwell, Sarah Darby

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    5 Citations (Scopus)

    Abstract

    Introduction: National cancer registration data were linked to the Primary Care Prescription Database (PCPD) in England. The level of endocrine therapy (ET) prescribed in women after a diagnosis of breast cancer was studied. Materials and methods: Cancer registrations for women diagnosed with breast cancer during 1995–2015, who survived to 31st March 2015, were linked to ET prescriptions issued during April–July 2015. Results: Among 369 277 survivors of breast cancer diagnosed during 1995–2015, 37% were prescribed ET during April–July 2015. Among women whose breast cancer diagnosis was after 31st July 2010, 81% of those recorded with oestrogen receptor positive (ER+ve) disease were prescribed ET compared with only 6% of those with ER-ve disease. Younger women usually received tamoxifen and older women usually received aromatase inhibitors. Discussion: The pattern of ET use observed in these data corresponds to that expected. This provides confidence in the potential of the PCPD for epidemiological research.

    Original languageEnglish
    Pages (from-to)185-189
    Number of pages5
    JournalCancer Epidemiology
    Volume61
    DOIs
    Publication statusPublished - Aug 2019

    Bibliographical note

    Funding Information:
    This work was supported by Cancer Research UK [grant number C8225/A21133 ].

    Funding Information:
    This work was supported by Cancer Research UK [grant number C8225/A21133]. Data for this study is based on patient-level information collected by the NHS, as part of the care and support of cancer patients. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE). The authors acknowledge and thank the entire team and NHS Business Services Authority for supporting and facilitating this partnership.

    Publisher Copyright:
    © 2019

    Keywords

    • Aromatase inhibitors
    • Breast neoplasm
    • Prescriptions
    • Tamoxifen
    • Therapeutics

    Fingerprint

    Dive into the research topics of 'Endocrine therapy in the years following a diagnosis of breast cancer: A proof of concept study using the primary care prescription database linked to cancer registration data'. Together they form a unique fingerprint.

    Cite this